About Slope

Transforming biospecimens into breakthroughs

At Slope, we believe that every biospecimen holds the potential to drive innovation in clinical research. By fundamentally transforming the way our industry manages the biospecimen lifecycle, we also empower researchers and clinical teams with real-time, high-quality data that drives faster, better informed decisions.

Slope ensures that the full potential of every sample is realized, unlocking the ability for biospecimens to fuel groundbreaking discoveries. When you partner with Slope, your biospecimens don’t just support research — they pave the way for scientific advancements that can save and improve lives.

Why we exist

Fix clinical research at its core

Slope was founded to solve a problem that is consistently being overlooked, despite its strain on the entire clinical trial ecosystem.

The problem

Clinical research sites do not have the tools to manage their biospecimens at scale.

The impact

Sponsors experience study delays, budget overruns, and regulatory risk due to a lack of proper oversight of the entire biospecimen lifecycle.

Our raison d'être

This chaos is what Slope was born to solve.
It’s why we exist.

Our Mantra

Protect the site experience

Slope is a site-first organization. Our focus is eliminating the chaos that hinders sites from focusing on what matters.

That’s why we’ve established a global network of NCI sites and AMCs, empowering them to control their clinical inventory and advance today’s most complex clinical trials.

Our Purpose

Patients are paramount

Slope is leading the charge in revolutionizing the biospecimen lifecycle for the betterment of patients everywhere.

We believe our site-centric approach and our mission to transform the way the industry manages the biospecimen lifecycle will enable us to make the biggest impact on patients’ lives. At Slope, patients are paramount.

"We want to empower sponsors, CROs, research sites, and labs to focus on advancing therapies rather than managing manual processes. Ultimately, this means faster trials, greater participation, better data, and more lives saved."